THE ONCOLOGY INSTITUTE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.55 USD | -3.53% |
|
-13.93% | -73.04% |
| May. 14 | Transcript : The Oncology Institute, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Earnings Flash (TOI) TOI MANAGEMENT LLC Reports Q1 Revenue $94.7M, vs. Street Est of $95.2M | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 714.2 | 122.8 | 150.4 | 39.08 | - |
| Enterprise Value (EV) 1 | 714.2 | 108.8 | 150.4 | 39.08 | 39.08 |
| P/E ratio | -60.9 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.49 x | 0.46 x | 0.09 x | 0.08 x |
| EV / Revenue | - | 0.49 x | 0.46 x | 0.09 x | 0.08 x |
| EV / EBITDA | - | -5.22 x | -5.83 x | -2.18 x | 21.9 x |
| EV / FCF | - | -1.82 x | -3.68 x | -1.82 x | -1.81 x |
| FCF Yield | - | -54.8% | -27.2% | -55% | -55.1% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 73,249 | 74,421 | 73,749 | 74,438 | - |
| Reference price 2 | 9.750 | 1.650 | 2.040 | 0.5250 | 0.5250 |
| Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 252.5 | 324.2 | 414.7 | 482.8 |
| EBITDA 1 | - | -23.54 | -25.8 | -17.91 | 1.783 |
| EBIT 1 | - | -79.96 | -77.02 | -23.67 | -3.824 |
| Operating Margin | - | -31.67% | -23.75% | -5.71% | -0.79% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | -10.93 | 1.657 | -83.07 | -54.04 | -35.27 |
| Net margin | - | 0.66% | -25.62% | -13.03% | -7.31% |
| EPS | -0.1600 | - | - | - | - |
| Free Cash Flow 1 | - | -67.28 | -40.88 | -21.51 | -21.53 |
| FCF margin | - | -26.65% | -12.61% | -5.19% | -4.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 64.98 | 71.42 | 76.19 | 80.22 | 82.04 | 85.79 | 94.67 | 103.3 | 107.5 | 109.1 |
| EBITDA 1 | - | -6.68 | -4.641 | -7.929 | -6.941 | -5.35 | -6.252 | -10.94 | -3.915 | -1.364 | -1.694 |
| EBIT 1 | - | -20.1 | -23.08 | -32.87 | -14.94 | -13.92 | -15.29 | -17.97 | -5.37 | -2.79 | -3.095 |
| Operating Margin | - | -30.93% | -32.32% | -43.14% | -18.62% | -16.97% | -17.82% | -18.98% | -5.2% | -2.59% | -2.84% |
| Earnings before Tax (EBT) | - | -2.698 | - | - | - | - | - | - | - | - | - |
| Net income 1 | -5.453 | -2.674 | -9.502 | - | -16.9 | -17.42 | -18.75 | -19.89 | -13 | -10.4 | -10.75 |
| Net margin | - | -4.12% | -13.3% | - | -21.06% | -21.23% | -21.86% | -21.01% | -12.58% | -9.67% | -9.85% |
| EPS | -0.0600 | -0.0300 | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/9/22 | 11/9/22 | 3/9/23 | 5/10/23 | 8/8/23 | 11/8/23 | 3/27/24 | 5/14/24 | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | 14 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -67.3 | -40.9 | -21.5 | -21.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 5.53 | 4.57 | 2.67 | 6.28 |
| Capex / Sales | - | 2.19% | 1.41% | 0.64% | 1.3% |
| Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.525
USD
Average target price
2
USD
Spread / Average Target
+280.95%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -73.04% | 39.08M | |
| +17.74% | 83.47B | |
| -29.66% | 69.72B | |
| 0.00% | 26.5B | |
| +3.06% | 17.69B | |
| -12.16% | 16.83B | |
| +2.47% | 15.7B | |
| +74.82% | 13.45B | |
| +73.52% | 12.81B | |
| +0.76% | 12.69B |
- Stock Market
- Equities
- TOI Stock
- Financials The Oncology Institute, Inc.
